UPB — Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology
$6.62
+$0.07 (+1.07%)
Upstream Bio, Inc. (UPB) is a biotechnology company listed on NASDAQ. It is led by E. Rand Sutherland M.D., M.P.H., MPH, based in 890 Winter Street, Waltham, MA, United States, 02451, with about 52 employees. Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Latest reported UPB revenue for 2025-09-30 was $683.0K. Net income was -$101.0M. Revenue was down 27.1% from 2025-06-30 to 2025-09-30. UPB currently screens at market cap $407.3M.
Use this UPB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the UPB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the UPB SEC filings page. Lician reads the product cache first so this HTML stays unique to Upstream Bio, Inc. even when a live quote feed is slow.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
UPB Key Statistics
Market Cap
$407.33M
Volume
432,792
Previous Close
$7.18
Day Range
$6.90 – $7.31
EPS
-$5.58
Revenue
$2.37M
Net Income
-$62.81M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-0.4%
Profit Margin
-2650.0%
Employees
52
UPB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $2.37M | $2.38M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$62.81M | -$20.54M |
| EPS (Diluted) | -$5.58 | -$12.95 |
Total Assets
$481.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$325.89M
Operating Cash Flow
-$59.17M
Free Cash Flow
$0.00
Upstream Bio, Inc. Company Information
- CEO & Director
- E. Rand Sutherland M.D., M.P.H., MPH
- Headquarters
- 890 Winter Street, Waltham, MA, United States, 02451
- Website
- upstreambio.com
- Phone
- 781 208 2466
- IPO / Founded
- 2024-10-11
- Sector
- Healthcare
- Industry
- Biotechnology